Tuesday, March 06, 2012

Schwartz Center Receives $500,000 Grant from the Amgen Foundation

Funds Support Expanded Efforts to Make Compassionate, Patient-Centered Care a National Healthcare Priority

BOSTON and THOUSAND OAKS, Calif., March 6, 2012 /PRNewswire/ -- The Schwartz Center for Compassionate Healthcare, a Boston-based nonprofit dedicated to strengthening the relationship between patients and their healthcare providers, today announced it has received a $500,000 grant from the Amgen Foundation. This grant will go toward the planned expansion of Schwartz Center Rounds® and to support the launch of a National Consensus Project.   

Read the rest of this entry

Posted in Press Releases

Friday, March 02, 2012

Amgen Announces Initial Results of Tender Offer for Outstanding Shares of Micromet, Inc. and Commencement of Subsequent Offering Period

THOUSAND OAKS, Calif., March 2, 2012 /PRNewswire/ -- Amgen ("Amgen") (NASDAQ: AMGN) announced today that all conditions to the closing of the tender offer (the "Offer") by a  wholly owned subsidiary, "Merger Sub", to acquire all outstanding shares of common stock of Micromet, Inc. ("Micromet") (NASDAQ: MITI) for $11.00 per share in cash have been satisfied. 

Read the rest of this entry

Posted in Press Releases

Thursday, February 23, 2012

Amgen to Present at the Citi 2012 Global Healthcare Conference

THOUSAND OAKS, Calif., Feb. 23, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Citi 2012 Global Healthcare Conference on Tuesday, Feb. 28, 2012, at the Waldorf Astoria in New York City, beginning at 4:30 p.m. Eastern Standard Time.

Read the rest of this entry

Posted in Press Releases

Wednesday, February 15, 2012

Amgen and Micromet Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Micromet

THOUSAND OAKS, Calif., Feb. 15, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Micromet, Inc. (NASDAQ: MITI) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended (HSR), in connection with Amgen’s tender offer for Micromet, was terminated early on Feb. 14, 2012 by the U.S. Federal Trade Commission.  The waiting period was scheduled to expire on Feb. 17, 2012.

Read the rest of this entry

Posted in Press Releases

Tuesday, February 14, 2012

Amgen Names Michael Severino, M.D., Senior Vice President, Global Development and Corporate Chief Medical Officer

THOUSAND OAKS, Calif., Feb. 14, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that Michael Severino, M.D., has been named senior vice president, Global Development and Corporate Chief Medical Officer, effective immediately.  Severino, 46, formerly vice president, Global Development at Amgen, will replace Sean Harper, M.D. Harper, 49, was appointed Amgen’s executive vice president, Research and Development.

Read the rest of this entry

Posted in Press Releases